Aurora Isoform Selectivity: Design and Synthesis of Imidazo[4,5-b]pyridine Derivatives as Highly Selective Inhibitors of Aurora-A Kinase in Cells

被引：63

作者：

Bavetsias, Vassilios ^{[1
]}

Faisal, Amir ^{[1
]}

Crumpler, Simon ^{[1
]}

Brown, Nathan ^{[1
]}

Kosmopoulou, Magda ^{[2
]}

Joshi, Amar ^{[3
]}

Atrash, Butrus ^{[1
]}

Perez-Fuertes, Yolanda ^{[1
]}

Schmitt, Jessica A. ^{[1
]}

Boxall, Katherine J. ^{[1
]}

Burke, Rosemary ^{[1
]}

Sun, Chongbo ^{[1
]}

Avery, Sian ^{[1
]}

Bush, Katherine ^{[1
]}

Henley, Alan ^{[1
]}

Raynaud, Florence I. ^{[1
]}

Workman, Paul ^{[1
]}

Bayliss, Richard ^{[2
,3
]}

Linardopoulos, Spiros ^{[1
,4
]}

Blagg, Julian ^{[1
]}

机构：

[1] Inst Canc Res, Div Canc Therapeut, Canc Res UK Canc Therapeut Unit, London SM2 5NG, England

[2] Inst Canc Res, Chester Beatty Labs, Div Struct Biol, London SW3 6JB, England

[3] Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England

[4] Inst Canc Res, Div Breast Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2013年 / 56卷 / 22期

关键词：

PALLADIUM-CATALYZED HETEROANNULATION; SMALL-MOLECULE INHIBITOR; ANTITUMOR-ACTIVITY; STRUCTURAL BASIS; N-MYC; ACTIVATION; OVEREXPRESSION; IDENTIFICATION; OPTIMIZATION; EXPRESSION;

D O I：

10.1021/jm401115g

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Aurora-A differs from Aurora-B/C at three positions in the ATP-binding pocket (L215, T217, and R220). Exploiting these differences, crystal structures of ligand- Aurora protein interactions formed the basis of a design principle for imidazo[4,S-b]pyridine-derived Aurora-A-selective inhibitors. Guided by a computational modeling approach, appropriate C7-imidazo[4,5-b]pyridine derivatization led to the discovery of highly selective inhibitors, such as compound 28c, of Aurora-A over Aurora-B. In HCT116 human colon carcinoma cells, 28c and 40f inhibited the Aurora-A L215R and R220K mutants with IC50 values similar to those seen for the Aurora-A wild type. However, the Aurora-A T217E mutant was significantly less sensitive to inhibition by 28c and 401 compared to the Aurora-A wild type, suggesting that the T217 residue plays a critical role in governing the observed isoform selectivity for Aurora-A inhibition. These compounds are useful small-molecule chemical tools to further explore the function of Aurora-A in cells.

引用

页码：9122 / 9135

页数：14

共 50 条

[1] PHENIX:: building new software for automated crystallographic structure determination [J].

Adams, PD ;

Grosse-Kunstleve, RW ;

Hung, LW ;

Ioerger, TR ;

McCoy, AJ ;

Moriarty, NW ;

Read, RJ ;

Sacchettini, JC ;

Sauter, NK ;

Terwilliger, TC .

ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2002, 58 :1948-1954

[2] A Class of 2,4-Bisanilinopyrimidine Aurora A Inhibitors with Unusually High Selectivity against Aurora B [J].

Aliagas-Martin, Ignacio ;

Burdick, Dan ;

Corson, Laura ;

Dotson, Jennafer ;

Drummond, Jason ;

Fields, Carter ;

Huang, Oscar W. ;

Hunsaker, Thomas ;

Kleinheinz, Tracy ;

Krueger, Elaine ;

Liang, Jun ;

Moffat, John ;

Phillips, Gail ;

Pulk, Rebecca ;

Rawson, Thomas E. ;

Ultsch, Mark ;

Walker, Leslie ;

Wiesmann, Christian ;

Zhang, Birong ;

Zhu, Bing-Yan ;

Cochran, Andrea G. .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (10) :3300-3307

[3]

[Anonymous], 2011, MOL OP ENV MOE VERS

[4] High expression of Aurora-B/Aurora and Ipl1-like midbody-associated protein (AIM-1) in astrocytomas [J].

Araki, K ;

Nozaki, K ;

Ueba, T ;

Tatsuka, M ;

Hashimoto, N .

JOURNAL OF NEURO-ONCOLOGY, 2004, 67 (1-2) :53-64

[5] THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].

BAILEY, S .

ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763

[6] Aurora-A: the maker and breaker of spindle poles [J].

Barr, Alexis R. ;

Gergely, Fanni .

JOURNAL OF CELL SCIENCE, 2007, 120 (17) :2987-2996

[7] Hit generation and exploration:: Imidazo[4,5-b] pyridine derivatives as inhibitors of Aurora kinases [J].

Bavetsias, Vassilios ;

Sun, Chongbo ;

Bouloc, Nathalie ;

Reynisson, Johannes ;

Workman, Paul ;

Linardopoulos, Spiros ;

McDonald, Edward .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (23) :6567-6571

[8] Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia [J].

Bavetsias, Vassilios ;

Crumpler, Simon ;

Sun, Chongbo ;

Avery, Sian ;

Atrash, Butrus ;

Faisal, Amir ;

Moore, Andrew S. ;

Kosmopoulou, Magda ;

Brown, Nathan ;

Sheldrake, Peter W. ;

Bush, Katherine ;

Henley, Alan ;

Box, Gary ;

Valenti, Melanie ;

Brandon, Alexis de Haven ;

Raynaud, Florence I. ;

Workman, Paul ;

Eccles, Suzanne A. ;

Bayliss, Richard ;

Linardopoulos, Spiros ;

Blagg, Julian .

JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (20) :8721-8734

[9] Imidazo[4,5-b]pyridine Derivatives As Inhibitors of Aurora Kinases: Lead Optimization Studies toward the Identification of an Orally Bioavailable Preclinical Development Candidates [J].

Bavetsias, Vassilios ;

Large, Jonathan M. ;

Sun, Chongbo ;

Bouloc, Nathalie ;

Kosmopoulou, Magda ;

Matteucci, Mizio ;

Wilsher, Nicola E. ;

Martins, Vanessa ;

Reynisson, Johannes ;

Atrash, Butrus ;

Faisal, Amir ;

Urban, Frederique ;

Valenti, Melanie ;

Brandon, Alexis de Haven ;

Box, Gary ;

Raynaud, Florence I. ;

Workman, Paul ;

Eccles, Suzanne A. ;

Bayliss, Richard ;

Blagg, Julian ;

Linardopoulos, Spiros ;

McDonald, Edward .

JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (14) :5213-5228

[10] Structural basis of Aurora-A activation by TPX2 at the mitotic spindle [J].

Bayliss, R ;

Sardon, T ;

Vernos, I ;

Conti, E .

MOLECULAR CELL, 2003, 12 (04) :851-862

← 1 2 3 4 5 →